$13B Salix-Valeant Merger Row Tossed In Del. Chancery
Delaware's Chancery Court late Thursday tossed a shareholder challenge to Salix Pharmaceuticals Ltd.'s $13.1 billion sale to Valeant Pharmaceuticals Inc., finding the two-count suit failed to support viable claims against either...To view the full article, register now.
Already a subscriber? Click here to view full article